Total Payments
$171,370
2024 Payments
$44,088
Companies
48
Transactions
680
Medicare Patients
9,524
Medicare Billing
$719,722
Payment Breakdown by Category
Other$111,880 (65.3%)
Research$33,559 (19.6%)
Food & Beverage$13,610 (7.9%)
Travel$6,181 (3.6%)
Consulting$5,652 (3.3%)
Education$488.01 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111,880 | 48 | 65.3% |
| Unspecified | $33,559 | 1 | 19.6% |
| Food and Beverage | $13,610 | 588 | 7.9% |
| Travel and Lodging | $6,181 | 31 | 3.6% |
| Consulting Fee | $5,652 | 1 | 3.3% |
| Education | $488.01 | 11 | 0.3% |
Payments by Type
General
$137,811
679 transactions
Research
$33,559
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $48,265 | 133 | $0 (2024) |
| Eli Lilly and Company | $34,905 | 15 | $0 (2024) |
| Amarin Pharma Inc. | $27,161 | 40 | $0 (2023) |
| Kowa Pharmaceuticals America, Inc. | $23,315 | 35 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $15,511 | 27 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $7,373 | 87 | $0 (2023) |
| Esperion Therapeutics, Inc. | $7,198 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,399 | 78 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $728.20 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $536.37 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,088 | 113 | Eli Lilly and Company ($34,905) |
| 2023 | $13,772 | 89 | Amgen Inc. ($12,486) |
| 2022 | $7,506 | 74 | Amgen Inc. ($6,399) |
| 2021 | $12,513 | 46 | Esperion Therapeutics, Inc. ($7,093) |
| 2020 | $8,777 | 41 | Amarin Pharma Inc. ($4,420) |
| 2019 | $13,824 | 66 | Amarin Pharma Inc. ($7,833) |
| 2018 | $13,708 | 94 | Amarin Pharma Inc. ($7,032) |
| 2017 | $57,182 | 157 | Kowa Pharmaceuticals America, Inc. ($22,321) |
All Payment Transactions
680 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: DIABETES | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $142.53 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $84.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/26/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/18/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $226.86 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $202.21 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $168.30 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | Cash or cash equivalent | $150.00 | General |
| 11/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | Food and Beverage | Cash or cash equivalent | $21.28 | General |
| Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 11/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $135.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/10/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $33,559 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,483 | 3,246 | $686,903 | $176,308 |
| 2022 | 18 | 2,428 | 3,331 | $721,720 | $182,410 |
| 2021 | 20 | 2,422 | 3,278 | $718,915 | $191,482 |
| 2020 | 20 | 2,191 | 3,092 | $692,297 | $169,522 |
Total Patients
9,524
Total Services
12,947
Medicare Billing
$719,722
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 293 | 467 | $227,837 | $68,023 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 365 | 455 | $165,541 | $42,847 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 67 | 67 | $46,297 | $11,581 | 25.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 189 | 193 | $46,706 | $10,189 | 21.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 534 | 810 | $47,790 | $9,400 | 19.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 52 | 53 | $38,849 | $7,754 | 20.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 55 | 70 | $24,010 | $7,120 | 29.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 101 | 101 | $26,361 | $6,194 | 23.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 519 | 608 | $24,320 | $4,083 | 16.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 46 | 47 | $11,374 | $2,703 | 23.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 122 | 127 | $6,223 | $1,417 | 22.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 16 | $3,840 | $1,082 | 28.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 32 | 32 | $4,224 | $942.21 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $2,964 | $873.95 | 29.5% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 32 | 33 | $2,937 | $680.14 | 23.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 27 | $2,025 | $526.75 | 26.0% |
| 93926 | Ultrasound of one leg arteries or artery grafts | Office | 2023 | 25 | 25 | $2,000 | $460.56 | 23.0% |
| 85610 | Blood test, clotting time | Office | 2023 | 13 | 103 | $3,605 | $432.60 | 12.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 247 | 412 | $200,644 | $59,278 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 380 | 510 | $185,130 | $48,008 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 75 | 75 | $51,825 | $11,501 | 22.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 527 | 867 | $51,153 | $9,929 | 19.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 69 | 113 | $38,759 | $9,914 | 25.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 180 | 184 | $44,528 | $9,864 | 22.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 50 | 50 | $36,583 | $8,326 | 22.8% |
About Dr. Robert Fishberg, MD
Dr. Robert Fishberg, MD is a Cardiovascular Disease healthcare provider based in Springfield, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871587345.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Fishberg, MD has received a total of $171,370 in payments from pharmaceutical and medical device companies, with $44,088 received in 2024. These payments were reported across 680 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($111,880).
As a Medicare-enrolled provider, Fishberg has provided services to 9,524 Medicare beneficiaries, totaling 12,947 services with total Medicare billing of $719,722. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Springfield, NJ
- Active Since 09/09/2005
- Last Updated 05/09/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1871587345
Products in Payments
- Repatha (Biological) $47,791
- Vascepa (Drug) $27,161
- Livalo (Drug) $23,315
- PRALUENT (Drug) $15,458
- XARELTO (Drug) $7,397
- NEXLIZET (Drug) $7,030
- EVKEEZA (Biological) $791.72
- VERQUVO (Drug) $511.56
- LEQVIO (Drug) $487.63
- ENTRESTO (Drug) $389.24
- Kerendia (Drug) $387.70
- Corlanor (Drug) $257.56
- WATCHMAN (Device) $253.00
- LifeVest (Device) $233.72
- JARDIANCE (Drug) $183.16
- PRALUENT ALIROCUMAB INJECTION (Biological) $183.01
- NEXLETOL (Drug) $167.95
- GoNitro (Drug) $149.00
- PRALUENT (Biological) $130.36
- Wegovy (Drug) $113.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Springfield
Tony De Martini, M.d, M.D
Cardiovascular Disease — Payments: $519,196
Cardiovascular Disease $519,196
Dr. Gerard Oghlakian, Md, MD
Cardiovascular Disease — Payments: $502,096
Cardiovascular Disease $502,096
David Powell, Md, MD
Cardiovascular Disease — Payments: $196,233
Cardiovascular Disease $196,233
Dr. Shady Henien, M.d, M.D
Cardiovascular Disease — Payments: $104,402
Cardiovascular Disease $104,402
Dr. Shang-Chiun Lee, Md, MD
Cardiovascular Disease — Payments: $97,193
Cardiovascular Disease $97,193
Jack Hall, Md, MD
Cardiovascular Disease — Payments: $88,257
Cardiovascular Disease $88,257